LivagenvsLL-37

Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.

Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.

As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.

LL-37 is the only cathelicidin-derived antimicrobial peptide in humans, cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophil granules. It functions as a critical component of the innate immune system's first line of defense, with both direct antimicrobial activity and sophisticated immunomodulatory signaling.

The direct antimicrobial mechanism relies on LL-37's amphipathic alpha-helical structure — one face is positively charged (cationic) while the other is hydrophobic. The cationic face electrostatically attracts the negatively charged phospholipid headgroups of bacterial membranes (which differ from mammalian membranes in their lipid composition and charge distribution). Once bound, the hydrophobic face inserts into the lipid bilayer, creating pores or disrupting membrane integrity through a 'carpet' or 'toroidal pore' mechanism. This physical membrane disruption kills bacteria, fungi, and enveloped viruses rapidly and is difficult for microbes to develop resistance against, unlike conventional antibiotics that target specific enzymes.

The immunomodulatory functions are equally important. LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL1) activation, recruiting immune cells to infection sites. It promotes macrophage phagocytosis and enhances the killing capacity of neutrophil extracellular traps (NETs). Critically, LL-37 neutralizes bacterial lipopolysaccharide (LPS/endotoxin), preventing the cytokine storm that leads to sepsis. It also stimulates angiogenesis through VEGF upregulation and promotes wound re-epithelialization by activating epidermal growth factor receptor (EGFR) transactivation. LL-37 production is upregulated by vitamin D (which is why vitamin D status affects innate immunity), and its expression is found in skin, airways, the gastrointestinal tract, and virtually all epithelial barrier tissues.